Clinical outcomes in chronic lymphocytic leukemia (CLL) have improved with targeted therapy, including Bruton tyrosine kinase inhibitors such as acalabrutinib.A semi-Markov model with 3 health stat...
3 March 2009 in The European Journal of Health Economics